Released May 13, 2026, before the open
10-Q filed May 13, 2026, 43 days after period end · 0001104659-26-059756
Q1 2026 · 10-Q
Revenue$33.75M$33.75M +233.7% vs Q1 2025+270.0% vs Q4 2025
Net Income$18.32M$18.32M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted$0.22$0.22 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income$21,146,000N/M
Operating Cash Flow$22,025,000N/M
Free Cash Flowderived$21,264,000N/M
Margins · derived
Operating margin62.7%+103.6 pt vs Q1 2025
Net margin54.3%+90.1 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $33.75M | $10.11M | $3.75M | $9.59M |
| Net Income | $18.32M | -$3.62M | -$4.60M | -$3.13M |
| EPS Diluted | $0.22 | -$0.05 | -$0.06 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR